A Living Organoid Biobank of Crohn's Disease Patients Reveals Distinct Clinical Correlates of Molecular Subtypes of Disease

Authors:

Harrison M. Penrose[2,3], Saptarshi Sinha[1], Courtney Tindle[1,2], Kameron Zablan[3], Helen N. Le[3], Jennifer Neill[3], Pradipta Ghosh[1,2, 3†¶], and Brigid S. Boland[3†¶]

Affiliations:

[1]*Department of Cellular and Molecular Medicine, University of California San Diego, La Jolla, CA, 92093.*

[2]*HUMANOID™ Center of Research Excellence (CoRE), University of California San Diego, La Jolla, CA, 92093.*

[3]*Department of Medicine, University of California San Diego, La Jolla, CA, 92093.*

Keywords: Patient-derived organoids, inflammatory bowel disease, personalized therapeutics, predictive disease models

†Senior corresponding authors:

Pradipta Ghosh, M.D.; prghosh@ucsd.edu

Brigid S. Boland, M.D.; bboland@health.ucsd.edu

¶Lead contacts:

Pradipta Ghosh, M.D.; prghosh@ucsd.edu

Brigid S. Boland, M.D.; bboland@health.ucsd.edu

GRAPHICAL ABSTRACT

In Brief:

In this work, Penrose et al. demonstrate the potential of patient-derived organoids (PDOs) as predictive tools in Crohn's disease (CD) that capture the past, present, and future of disease behavior, thereby advancing PDO-informed precision medicine beyond oncology into complex inflammatory diseases.

HIGHLIGHTS

- A living PDO biobank identified two molecular CD subtypes with distinct functional phenotypes.

- PDO subtyping tracked severity of ileal disease, prior surgery and future disease progression.

- Colonic immune dysfunction may drive ileal-CD, independent of colonic involvement.

- Colonic CD-PDOs are dynamic platforms for outcome-deterministic therapeutic testing.

SUMMARY

Current clinical decision-making lacks reliable preclinical models to predict patient outcomes. Here, we establish patient-derived organoids (PDOs) as predictive tools in Crohn's disease (CD), a complex, heterogeneous disorder. Using a living biobank of adult stem cell-derived colonic-PDOs, we identified two molecular CD subtypes—Immune-Deficient Infectious CD (*IDICD*) and Stress and Senescence-Induced Fibrostenotic CD (*S2FCD*)—each with distinct genomic, transcriptomic and functional profiles, along with paired therapeutics. By prospectively linking colonic PDO-derived phenotypes to real-world patient outcomes, we uncovered that while *S2FCD* associates with severe colonic disease, *IDICD* associates with severe ileal disease, prior ileocecal surgery, and future disease progression. This approach transforms PDOs from static descriptive models into dynamic tools that capture the past, present, and future of disease behavior and reveals their utility as patient-specific predictive platforms, extending their use beyond oncology to complex inflammatory diseases. Findings also suggest that colonic immune dysfunction may drive ileal-CD, independent of colonic involvement.

BRIEF REPORT

INTRODUCTION

Inflammatory Bowel Diseases (IBD), encompassing Crohn's disease (CD) and ulcerative colitis (UC), are chronic inflammatory disorders of the gastrointestinal tract with no perfect preclinical model or cure[1]. Disease pathogenesis and progression are driven by remitting, relapsing periods of inflammation involving dysregulated interactions between the host genome, microbiome, gut immune system, and environmental triggers[2]. CD, in particular, is a remarkably heterogeneous disease, exhibiting highly variable clinical presentations and disease trajectories that remain difficult to predict. While host genetics have partly explained certain disease characteristics (i.e. anatomic location), they fail to account for variations in disease behavior, therapeutic response, environmental susceptibility, and complications, highlighting the need for personalized treatment strategies[3]. It also remains a challenging disease to model; accurately recapitulating all contributing factors in any one murine model has remained out of reach[4]. Recent studies using patient-derived organoids (PDOs) have shown their ability to recapitulate key features of IBD including characteristic aspects of epithelial dysfunction and impaired barrier function while preserving disease heterogeneity; however, existing studies are limited by small sample size and narrow focus[5,6].

To address this unmet need, we recently developed a living biobank of adult stem cell (AdSC) derived organoids isolated exclusively from fresh *colonic* mucosal biopsies at the UC San Diego Biobank. We prioritized the colon over the ileum, as it is affected in approximately 60–70% of Crohn's disease cases[7]. Additionally, we used AdSCs instead of induced pluripotent stem cells (iPSCs), as AdSCs retain tissue-specific identity and epigenetic landscape shaped by the unique exposome of their organ of origin[8-13]. Our study captured prospectively biobanked patient-derived colonic PDOs from 24 CD patients across all clinical subtypes, reflecting the diversity of patients treated at tertiary care centers[14] in the United States. A multi-omics approach that integrated deep phenotyping with transcriptomic and genomic analyses determined that despite patient diversity and real-world heterogeneity in disease manifestation, all PDOs fell into two molecular subtypes: *Immune-Deficient Infectious CD (IDICD)* and *Stress and Senescence-Induced Fibrostenotic CD (S2FCD)*[14]. These subtypes demonstrated remarkable internal consistency across transcriptomic, genomic, and phenotypic profiles while exhibiting distinct morphometric and functional differences. Briefly, they represent non-overlapping, fundamental defects in colonic epithelial cells: *IDICD* exhibits paradoxical immunosuppression, i.e., inflammation in the setting of impaired pathogen clearance and insufficient cytokine response, frequently harboring key CD-associated risk alleles (*NOD2*, *ATG16L1*) and showing skewed epithelial differentiation[14]. In contrast, the *S2FCD* exhibits cellular senescence and a senescent-associated secretory phenotype (SASP), genotoxic stress (double-stranded DNA breaks), as well as a profibrotic transcriptomic profile. *S2FCD* also harbors higher mutational burden in the YAP1–IL-18 pathway[14], which has been implicated in telomere instability–associated epithelial inflammation, a distinctive cellular feature of SASP. These distinctions also carried therapeutic consequences: each subtype required its own targeted intervention, and the efficacy of one approach did not translate to the other[14]—highlighting the lack of cross-over efficacy and the need for tailored therapeutic strategies.

Here, we build upon that foundation, integrating multi-omics analysis and clinical phenotyping to explore how these molecular subtypes correlate with real-world patient outcomes. Our findings establish colonic PDOs as dynamic, outcome-predictive tools that bridge molecular classification and disease trajectory—bringing precision medicine in CD into sharper focus.

RESULTS

Although prior work characterized how each molecular subtype of CD-PDO differed from healthy PDOs, head-to-head comparisons were not performed. Here, we analyzed differential gene expression patterns between *IDICD* and *S2FCD* to identify subtype-specific genes, cellular pathways, and enriched biological processes (**Fig 1A, B**; see **Table S1** for all DEGs). Relevant to IBD, *IDICD* was characterized by upregulation of genes involved in inflammation-immune regulation (*IL33, F2RL1*), enzymes within the sulfation pathway that are critical for metabolism, detoxification, and excretion of various substances (*SULT1A4, PAPSS2*), and epithelial-stem cell maintenance (*KLF4*). Whereas *S2FCD* demonstrated enrichment of genes related to Wnt signaling and development (*WNT6, NOTUM*), epithelial barrier integrity (*LCN2, CDH11*), and immune activation (*CD40, TNFRSF6B*) (**Fig 1A**). A KEGG (Kyoto Encyclopedia of Genes and Genomes) pathway enrichment analysis showed unique enrichment of biological pathways for each molecular subtype (**Fig 1B**). As predicted in the setting of senescence and SASP, *S2FCD* was enriched in pathways related to stem cell signaling, including Wnt and cytokine pathways that regulate these processes. Surprisingly, despite their derivation from the colon, *IDICD* was associated with retinol metabolism, and bile acid-related pathways which are processes that are typically restricted to the small intestine, particularly the ileum[15,16] where both are absorbed and/or processed by enterocytes.

Together these findings indicate that *IDICD* and *S2FCD* as biologically distinct epithelial subtypes of CD, each defined by distinct transcriptional programs and pathway enrichment that may reflect unique mechanisms underlying disease pathogenesis and influence propensity for variable clinical presentation.

To evaluate the potential clinical implications and ability to predict disease progression associated with these biologically distinct molecular subtypes, next we asked whether *IDICD* and *S2FCD* correlated with meaningful patient outcomes by performing univariate logistic regression analyses[17] (UV) across a comprehensive clinical dataset (**Table S2**). This approach allows us to examine how molecular subtypes of colonic CD-PDOs (independent predictor variable) affects the likelihood of any clinical outcome (dependent variable), which can be either binary (e.g., yes/no, worsening/improving) or reflect a continuum of discretely scored entities (e.g., Simple Endoscopic Score [SES] of disease severity). Significant relationships between the two variables estimate the probability of the outcome based on the CD-PDO subtype. Despite the inclusion of a wide array of variables, a positive and significant correlation emerged between *IDICD* subtype and severity of ileal disease (**Fig 1C**, "Baseline", i.e., at the time of tissue diversion), as measured objectively by the SES-CD for the ileum[18]. Significance was also noted between *IDICD* and a history of surgical resection of the ileocecal region and/or penetrating disease (B3) behavior (p<0.05), as well as lack of improvement in

clinical symptoms based on change in patient reported outcome (PRO) scores over the prospective 5-year follow-up period (**Fig 1C**). By contrast, the *S2FCD* molecular subtype was associated with severity of colonic disease (**Fig 1C**, "Baseline"), as measured objectively by total colonic SES-CD ($p < 0.05$) (**Fig 1C**). Three other variables trended towards significance ($p < 0.1$, indicative of a <10% probability that the observed relationship is due to random chance): *IDICD* was associated with severity of ileal disease during follow-up and *S2FCD* was associated with inflammatory disease that is restricted to the mucosa (non-stricturing, non-penetrating; NSNP-CD) and predominantly isolated to the colon. These findings suggest that while *IDICD* is associated with predominantly progressive ileal disease, *S2FCD* primarily presents as isolated colonic-CD. To control for potential confounders, multivariate (MV) analysis was carried out on the covariates that emerged as significant ($p < 0.1$) and/or trending towards significance in the UV analysis. None of the covariates showed statistically significant associations with PDO subtype, which indicated that covariates could be highly correlated, i.e., interdependent (**Supplementary Figure 1**).

The emergence of these associations in a small cohort suggests that the relationships between *IDICD* and key clinical outcomes—such as prior need for surgery, current endoscopic disease severity, and future disease progression—are substantial. It is noteworthy that our PDO cohort is comprised of 25% ileal (n = 6), 46% ileocolonic (n = 11) and 29% isolated colonic (n = 7), mirroring the proportions observed in the real world[7]. The UV analysis suggests that the cellular defects in *IDICD* may be a causal factor in severe and progressive ileal disease. However, the MV model indicates that these defects likely influence the past, present, and future course of the disease with equal probability—reflecting a disease continuum.

DISCUSSION

The major discovery we report here is that two distinct molecular subtypes of colon-derived CD PDOs have equally distinct clinical correlates—specifically, *IDICD* tracks with severity of ileal disease, whereas *S2FCD* tracks with severity of colonic disease. In the case of *IDICD*-PDOs, they appeared to also capture the continuum of ileal disease, showing strong associations with prior ileocecal surgery and forecasting disease progression. Because prior work[14] emphasized the need for pairing therapeutics to reverse the cellular defects unique to each molecular subtype, these findings highlight the utility of colonic PDOs as powerful dynamic platforms for therapeutic testing and predictive tools in CD. In doing so, this work elevates CD-PDOs to the levels of cancer-PDOs, which have been widely validated as personalized precision oncology models capable of capturing the molecular and functional complexity of individual tumors to forecast disease progression and therapeutic response[19-24]. Our findings suggest that by faithfully recapitulating disease evolutionary trajectories, CD-PDOs can enable personalized risk stratification and real-time therapeutic testing, bridging the gap between in vitro models and clinical outcomes.

Our study also revealed two other findings. First, it showed that defects in the colonic epithelium may serve as a useful surrogate for ileal disease and suggests that innate immune dysfunction in the colonic epithelium of *IDICD* subtype may be a driver of disease trajectory in isolated ileal or ileocolonic-CD. Mechanistically, both systemic and local factors may be involved. Systemic immune mediators, such as

cytokine or hormonal signaling, could influence immune responses in the ileum, which features dense immune structures (Peyer's patches, intraepithelial lymphocytes). Locally, retrograde migration of colonic microbes via reverse peristalsis—particularly in the setting of dysbiosis and structural obstruction (as seen in stricturing or penetrating disease)—may contribute to ileal inflammation in *IDICD*.

Second, despite using *colonic* PDOs to investigate disease drivers, our findings reinforce the classification of CD into ileal-dominant versus isolated colonic phenotypes—regardless of clinical heterogeneity—aligning with prior efforts to stratify CD along these lines (**Fig 1D**). Prior transcriptomic analyses of colonic mucosal biopsies have revealed gene expression patterns that distinguish ileal-dominant from colonic CD, with epigenomic regulation differing by disease location[25]. Multi-omics analyses of stool samples have identified microbial, metabolic, and immune signatures—such as bile acid–rich environments and immunoproteomic profiles—that differ between ileal and colonic-CD[26,27]. At the cellular level, collagen-producing myofibroblast populations are enriched in ileal disease[28], while Th1/Th17 populations show variable enrichment depending on disease location[29]. Although not specifically derived from colonic mucosa, genetic studies have supported this subclassification: *NOD2* and *ATG16L1* SNPs have been linked to ileal-CD, while *MHC* SNPs associate with colonic disease[30]. This is also supported through epidemiologic studies showing that smoking is associated with ileal-CD, whereas colonic-CD is more prevalent in females[31-33]. While previous studies have approached this distinction through genetic, microbial, and transcriptomic lenses, our organoid-based classification provides a functional, epithelial–driven framework that complements and strengthens this evolving model of disease subtypes in CD.

We also postulate this clinical-phenome dimension may enable actionable therapeutic stratification. The limited efficacy of numerous conventional immunosuppressive therapies in ileal-CD[34], which is more prone to complications [35,36], may be explained by our prior findings demonstrating the need for rectifying microbial clearance pathways such as dual PPARα/γ agonists to restore epithelial defense mechanisms in *IDICD*[14,37,38]. Given that *IDICD*-PDOs show insufficient cytokine response in the setting of infection[14], it could explain why ileal-CD is less responsive to a broad range of anti-cytokine therapies, including anti-TNFα, anti-IL12/23, and likely JAK inhibitors, all of which demonstrate higher efficacy in colonic CD and UC[34,39,40]. By contrast, the purported efficacy of JAK inhibitors in colonic CD may be explained by our prior findings demonstrating the need to target oxidative stress and senescence pathways—hallmarks of *S2FCD*—which were reversed in colonic-PDOs using senolytic agents such as Pacritinib[14,41]. The clinical correlation of *S2FCD* with active, but mucosa-restricted colonic inflammation (mimicking UC) is likely because of stem cell dysfunction and derailed Wnt signaling that is observed in the setting of fibrosis[42]. Together, these molecular subtypes appear to impact clinical phenotypes and disease activity, showing promise in aligning treatment strategies with disease-driving pathways. Ultimately, the utility of *IDICD*-PDOs to shape therapeutics in ileal-CD will require understanding the basis for innate immune dysfunction. Drugs that successfully enhanced microbial clearance in these *IDICD*-PDOs[14] provide an impetus to spare anti-cytokine strategies and instead, develop first-in-class pro-clearance therapeutics to treat ileal-CD.

LIMITATIONS OF STUDY

A larger cohort and longitudinal PDO assessments could enhance rigor and provide deeper insights. However, the representative nature of the cohort when it comes to the distribution of ileal vs colonic-CD, consistency of covariates, and the lack of independent variables emerging support the relevance of our findings despite the sample size. Validation in an independent cohort, preferably through a longitudinal study, would further strengthen conclusions. Although we posit that current and emerging literature suggests the possibility that the derailment of colonic innate immune functions may trigger and/or perpetuate ileal disease, we do not explore mechanisms here. Regardless of the knowledge gaps in our understanding of how regional or systemic immune differences shape ileal disease progression, our findings expose clinically meaningful correlates of fundamental cellular defects in CD that may prognosticate and inform choice of individualized, mechanism-driven therapeutic strategies in an area of unmet need.

ACKNOWLEDGEMENTS

Funding for this work was supported by the Leona M. and Harry B. Helmsley Charitable Trust (to P.G.). Other sources of support include National Institutes of Health (NIH) grants AI141630, UG3TR003355 and AI55696 to P.G.; NIH grants P30DK120515 to B.S.B. H.M.P. was supported by The California Institute of Regenerative Medicine Training Grant for Clinical Fellows through Sanford-Burnham Prebys-UC San Diego. S.S. was supported by the American Association of Immunologists Intersect Fellowship Program for Computational Scientists and Immunologists.

AUTHOR CONTRIBUTIONS

H.M.P., S.S., C.T., B.S.B., and P.G. conceptualized, supervised, administered the project. B.S.B and P.G acquired funding to support it. Computational analyses were carried out by S.S. under the supervision of P.G. K.Z., H.N.L., J.N., and B.S.B provided key resources for human subjects and were responsible for the selection and enrolling of patients into this study. H.M.P., S.S. and P.G. prepared figures for data visualization. H.M.P., B.S.B and P.G. wrote the original draft. H.M.P, S.S., C.T., B.S.B, and P.G. reviewed and edited the draft. All co-authors approved the final version of the manuscript.

COMPETING INTERESTS

BSB has received research grants from Merck, Mirador, Gilead. BSB has served as a consultant for Abbvie, Merck, and Celltrion.

Figure 1. **Colonic PDOs hint at distinct pathophysiology and outcomes in ileal versus colonic-CD.**

(A) _Left_: Workflow in creating a 'living biobank' of colonic PDOs with prospective follow-up on disease outcome. _Right_: Volcano plot depicting DEGs from RNA-seq in *IDICD* vs. *S2FCD*, where the interrupted line marks log2FC = 1.0. For clarity, gene symbols are shown only for the most interesting genes relevant to CD/IBD.

(B) Lollipop Bar Plots of KEGG pathways associated with DEGs [log2FC ≥ 1.5] in A.

(C) Univariate analysis models of *IDICD* vs. *S2FCD* subtypes as a linear combination of all variables in a CD cohort. The coefficient of each variable (at the center) with 95% CI (as error bars) and the p values are illustrated. The p-value for each term tests the null hypothesis that the coefficient is equal to zero (no effect). .p ≤ 0.1; *p ≤ 0.05; **p ≤ 0. 01. Bold = significant co-variates. See **Supplementary Figure S1** for multivariate analysis among the significant covariates. SES-CD, Simple endoscopic score for Crohn's Disease; IC, ileocecal; EIM, extraintestinal manifestations. Montreal classification for disease behavior: L1 – ileal, L2 – colonic, L3 – ileocolonic; B1 – non-stricturing, non-penetrating; B2 – stricturing; B3 – penetrating. Δ refers to the delta change between baseline and follow-up SES-CD or PRO scores.

(D) Schematic summarizes pertinent literature that converges on the notion that all CDs, regardless of how they were evaluated across scales—genetic, epigenetic, cellular, exposome (stool composition), or clinical/epidemiologic correlates—appear to be broadly classifiable as ileal and/or ileocolonic vs. isolated colonic disease. Colon-focused analyses that consistently arrived at that conclusion, even when uninvolved, are highlighted.

STAR METHODS

KEY RESOURCES TABLE

Reagent or Resource	Source	Identifier
Deposited data		
RNA sequencing data of PDOs from the colons of patients with CD	Re-analysis of GSE192819[14]	Pending new GSE ID
Software and algorithms		
GraphPad Prism	GraphPad Prism	RRID:SCR_002798
DESeq2 (v 1.40.2)	https://github.com/thelovelab/DESeq2	
Statsmodels (v 0.14.4)	https://www.statsmodels.org/stable/index.html	
Matplotlib (v 3.10.1)	https://matplotlib.org/	

RESOURCE AVAILABILITY

Lead Contacts

Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contacts, Pradipta Ghosh, prghosh@ucsd.edu and Brigid S. Boland, bboland@health.ucsd.edu.

Materials availability

This study utilizes data generated from an organoid biobank. These materials are available from the lead contact with a completed Materials Transfer Agreement and patented technology agreement (Ghosh) following the guidelines of the Regents of the University of California, San Diego.

Data and code availability

Newly generated transcriptomic datasets reported in this paper involve re-analysis of GSE192819 which has been deposited in NCBI's Gene Expression Omnibus. The new GSE ID assignment is currently pending.

This paper did not generate or use custom computer codes.

Any additional information required to reanalyze the data reported in this work paper is available from Lead Contact upon request.

SUBJECT DETAILS AND BIOINFORMATICS APPROACH

Human Subjects Utilized in Current Study

Previously generated CD PDOs, which underwent comprehensive multi-omics analyses for molecular phenotyping[14], were utilized for univariate and multivariate analyses. In brief, patients were recruited during routine colonoscopy procedures at the University of California, San Diego (UCSD) IBD Center. This study was conducted under an Institutional Review Board (IRB)-approved protocol in compliance with the Human Research Protection Program (HRPP) (Project ID# 1132632; PIs: Boland and Sandborn). Each participant provided written informed consent for the collection of colonic biopsies, the derivation of 3D organoids, and the use of associated clinical metadata for research purposes. The isolation and biobanking of organoids from colonic biopsies were conducted under a separate IRB-approved protocol (Project ID# 190105; PIs: Ghosh and Das) at the UCSD HUMANOID Center of Research Excellence (CoRE). All human subject data—including age, gender, and disease history—were de-identified and handled in accordance with HIPAA regulations. The study was designed and conducted following the ethical principles outlined in the Declaration of Helsinki.

Clinical Data Collection & Analysis

For CD patients, univariate analyses were performed using a comprehensive set of clinical parameters, including patient demographics (i.e. gender, age, ethnicity); disease classification and phenotype, i.e. Montreal classification, history of stricturing disease, prior ileocecal resection; disease activity indices, i.e. patient reported outcomes (PRO)[43,43] Simple Endoscopic Score for Crohn's Disease (SES-CD)[18]; additional clinical parameters included therapeutics history, i.e. use of advanced therapies and treatment response, location of biopsy source, and PDO molecular subtype. See **Table S2** for full list of clinical features.

Organoid Isolation from Colonic Specimens

PDOs were isolated from colonic tissue specimens collected from CD subjects using established crypt isolation protocols as previously summarized[14]. These intestinal crypts, which contain crypt-base columnar (CBC) cells, were enzymatically dissociated and processed for 3D organoid culture. Full details of organoid isolation, propagation, and molecular subtyping can be found in Tindle et al.[14]. Only CD subjects were included in the current study.

Computational Methods

Differentially expressed genes and pathway enrichment: Differentially expressed genes were identified using the DESeq2 package in R. A volcano plot was generated using the Matplotlib library (v 3.10.1) in Python. Pathway enrichment analysis was performed using ShinyGO 0.82.

Univariate and multivariate regression analyses: These were conducted across all clinical parameters, with molecular subtypes treated as a binary base variable. The Ordinary Least Squares (OLS) regression was performed using the statsmodels module in Python. The p-value for each term tests the null hypothesis that the corresponding coefficient equals zero (i.e., no effect).

SUPPLEMENTAL INFORMATION

Primary supplemental PDF: Supplemental figure and legend (**Supplementary Figure S1**).

Table S1: Differentially expressed genes between *IDICD* and *S2FCD* molecular subtypes of CD

Table S2: Excel datasheet with univariate and multivariate analyses of CD patients analyzed in this current study

REFERENCES

1. Baumgart, D.C., and Le Berre, C. (2021). Newer Biologic and Small-Molecule Therapies for Inflammatory Bowel Disease. N Engl J Med *385*, 1302-1315. 10.1056/NEJMra1907607.

2. Torres, J., Mehandru, S., Colombel, J.F., and Peyrin-Biroulet, L. (2017). Crohn's disease. Lancet *389*, 1741-1755. 10.1016/S0140-6736(16)31711-1.

3. Torres, J., and Colombel, J.F. (2016). Genetics and phenotypes in inflammatory bowel disease. Lancet *387*, 98-100. 10.1016/S0140-6736(15)00464-X.

4. DeVoss, J., and Diehl, L. (2014). Murine models of inflammatory bowel disease (IBD): challenges of modeling human disease. Toxicol Pathol *42*, 99-110. 10.1177/0192623313509729.

5. Lee, C., An, M., Joung, J.G., Park, W.Y., Chang, D.K., Kim, Y.H., and Hong, S.N. (2022). TNFalpha Induces LGR5+ Stem Cell Dysfunction In Patients With Crohn's Disease. Cell Mol Gastroenterol Hepatol *13*, 789-808. 10.1016/j.jcmgh.2021.10.010.

6. d'Aldebert, E., Quaranta, M., Sebert, M., Bonnet, D., Kirzin, S., Portier, G., Duffas, J.P., Chabot, S., Lluel, P., Allart, S., et al. (2020). Characterization of Human Colon Organoids From Inflammatory Bowel Disease Patients. Front Cell Dev Biol *8*, 363. 10.3389/fcell.2020.00363.

7. Mills, S., and Stamos, M.J. (2007). Colonic Crohn's disease. Clin Colon Rectal Surg *20*, 309-313. 10.1055/s-2007-991030.

8. Huch, M., Knoblich, J.A., Lutolf, M.P., and Martinez-Arias, A. (2017). The hope and the hype of organoid research. Development *144*, 938-941. 10.1242/dev.150201.

9. Poetsch, M.S., Strano, A., and Guan, K. (2022). Human Induced Pluripotent Stem Cells: From Cell Origin, Genomic Stability, and Epigenetic Memory to Translational Medicine. Stem Cells *40*, 546-555. 10.1093/stmcls/sxac020.

10. Doss, M.X., and Sachinidis, A. (2019). Current Challenges of iPSC-Based Disease Modeling and Therapeutic Implications. Cells *8*. 10.3390/cells8050403.

11. Zhao, D., Ravikumar, V., Leach, T.J., Kraushaar, D., Lauder, E., Li, L., Sun, Y., Oravecz-Wilson, K., Keller, E.T., Chen, F., et al. (2024). Inflammation-induced epigenetic imprinting regulates intestinal stem cells. Cell Stem Cell *31*, 1447-1464 e1446. 10.1016/j.stem.2024.08.006.

12. van de Wetering, M., Francies, H.E., Francis, J.M., Bounova, G., Iorio, F., Pronk, A., van Houdt, W., van Gorp, J., Taylor-Weiner, A., Kester, L., et al. (2015). Prospective derivation of a living organoid biobank of colorectal cancer patients. Cell *161*, 933-945. 10.1016/j.cell.2015.03.053.

13. Dennison, T.W., Edgar, R.D., Payne, F., Nayak, K.M., Ross, A.D.B., Cenier, A., Glemas, C., Giachero, F., Foster, A.R., Harris, R., et al. (2024). Patient-derived organoid biobank identifies epigenetic dysregulation of intestinal epithelial MHC-I as a novel mechanism in severe Crohn's Disease. Gut *73*, 1464-1477. 10.1136/gutjnl-2024-332043.

14. Tindle, C., Fonseca, A.G., Taheri, S., Katkar, G.D., Lee, J., Maity, P., Sayed, I.M., Ibeawuchi, S.R., Vidales, E., Pranadinata, R.F., et al. (2024). A living organoid biobank of patients with Crohn's disease reveals molecular subtypes for personalized therapeutics. Cell Rep Med *5*, 101748. 10.1016/j.xcrm.2024.101748.

15. Geng, T., Bao, S., Sun, X., Ma, D., Zhang, H., Ge, Q., Liu, X., and Ma, T. (2023). A clarification of concepts related to the digestion and absorption of carotenoids and a new standardized carotenoids bioavailability evaluation system. Food Chem *400*, 134060. 10.1016/j.foodchem.2022.134060.

16. Geyer, J., Wilke, T., and Petzinger, E. (2006). The solute carrier family SLC10: more than a family of bile acid transporters regarding function and phylogenetic relationships. Naunyn Schmiedebergs Arch Pharmacol *372*, 413-431. 10.1007/s00210-006-0043-8.

17. Richter, A.N., and Khoshgoftaar, T.M. (2018). A review of statistical and machine learning methods for modeling cancer risk using structured clinical data. Artif Intell Med *90*, 1-14. 10.1016/j.artmed.2018.06.002.

18. Daperno, M., D'Haens, G., Van Assche, G., Baert, F., Bulois, P., Maunoury, V., Sostegni, R., Rocca, R., Pera, A., Gevers, A., et al. (2004). Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. Gastrointest Endosc *60*, 505-512. 10.1016/s0016-5107(04)01878-4.

19. Yao, Y., Xu, X., Yang, L., Zhu, J., Wan, J., Shen, L., Xia, F., Fu, G., Deng, Y., Pan, M., et al. (2020). Patient-Derived Organoids Predict Chemoradiation Responses of Locally Advanced Rectal Cancer. Cell Stem Cell *26*, 17-26 e16. 10.1016/j.stem.2019.10.010.

20. Ooft, S.N., Weeber, F., Dijkstra, K.K., McLean, C.M., Kaing, S., van Werkhoven, E., Schipper, L., Hoes, L., Vis, D.J., van de Haar, J., et al. (2019). Patient-derived organoids can predict response to chemotherapy in metastatic colorectal cancer patients. Sci Transl Med *11*. 10.1126/scitranslmed.aay2574.

21. Vlachogiannis, G., Hedayat, S., Vatsiou, A., Jamin, Y., Fernandez-Mateos, J., Khan, K., Lampis, A., Eason, K., Huntingford, I., Burke, R., et al. (2018). Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. Science *359*, 920-926. 10.1126/science.aao2774.

22. Wang, T., Tang, Y., Pan, W., Yan, B., Hao, Y., Zeng, Y., Chen, Z., Lan, J., Zhao, S., Deng, C., et al. (2023). Patient-Derived Tumor Organoids Can Predict the Progression-Free Survival of Patients With Stage IV Colorectal Cancer After Surgery. Dis Colon Rectum *66*, 733-743. 10.1097/DCR.0000000000002511.

23. Tiriac, H., Belleau, P., Engle, D.D., Plenker, D., Deschenes, A., Somerville, T.D.D., Froeling, F.E.M., Burkhart, R.A., Denroche, R.E., Jang, G.H., et al. (2018). Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer. Cancer Discov *8*, 1112-1129. 10.1158/2159-8290.CD-18-0349.

24.   Wensink, G.E., Elias, S.G., Mullenders, J., Koopman, M., Boj, S.F., Kranenburg, O.W., and Roodhart, J.M.L. (2021). Patient-derived organoids as a predictive biomarker for treatment response in cancer patients. NPJ Precis Oncol *5*, 30. 10.1038/s41698-021-00168-1.

25.   Weiser, M., Simon, J.M., Kochar, B., Tovar, A., Israel, J.W., Robinson, A., Gipson, G.R., Schaner, M.S., Herfarth, H.H., Sartor, R.B., et al. (2018). Molecular classification of Crohn's disease reveals two clinically relevant subtypes. Gut *67*, 36-42. 10.1136/gutjnl-2016-312518.

26.   T, N., L, R., A, K., R, P., I, A., FM, K., and U, G. (2016 Feb). Distinct Microbiotas are Associated with Ileum-Restricted and Colon-Involving Crohn's Disease - PubMed. Inflammatory bowel diseases *22*. 10.1097/MIB.0000000000000662.

27.   Gonzalez, C.G., Mills, R.H., Zhu, Q., Sauceda, C., Knight, R., Dulai, P.S., and Gonzalez, D.J. (2022). Location-specific signatures of Crohn's disease at a multi-omics scale. Microbiome *10*, 133. 10.1186/s40168-022-01331-x.

28.   Kong, L., Pokatayev, V., Lefkovith, A., Carter, G.T., Creasey, E.A., Krishna, C., Subramanian, S., Kochar, B., Ashenberg, O., Lau, H., et al. (2023). The landscape of immune dysregulation in Crohn's disease revealed through single-cell transcriptomic profiling in the ileum and colon. Immunity *56*, 444-458 e445. 10.1016/j.immuni.2023.01.002.

29.   Kredel, L.I., Jodicke, L.J., Scheffold, A., Grone, J., Glauben, R., Erben, U., Kuhl, A.A., and Siegmund, B. (2019). T-cell Composition in Ileal and Colonic Creeping Fat - Separating Ileal from Colonic Crohn's Disease. J Crohns Colitis *13*, 79-91. 10.1093/ecco-jcc/jjy146.

30.   Cleynen, I., Boucher, G., Jostins, L., Schumm, L.P., Zeissig, S., Ahmad, T., Andersen, V., Andrews, J.M., Annese, V., Brand, S., et al. (2016). Inherited determinants of Crohn's disease and ulcerative colitis phenotypes: a genetic association study. Lancet *387*, 156-167. 10.1016/S0140-6736(15)00465-1.

31.   Parkes, G.C., Whelan, K., and Lindsay, J.O. (2014). Smoking in inflammatory bowel disease: impact on disease course and insights into the aetiology of its effect. J Crohns Colitis *8*, 717-725. 10.1016/j.crohns.2014.02.002.

32.   Subramanian, S., Ekbom, A., and Rhodes, J.M. (2017). Recent advances in clinical practice: a systematic review of isolated colonic Crohn's disease: the third IBD? Gut *66*, 362-381. 10.1136/gutjnl-2016-312673.

33.   Villafruela Cives, M. (2009). Re: "The risk of oral contraceptives in the etiology of inflammatory bowel disease: a meta-analysis". Response to Cornish et al. Am J Gastroenterol *104*, 534-535. 10.1038/ajg.2008.70.

34.   Atreya, R., Bojarski, C., Kuhl, A.A., Trajanoski, Z., Neurath, M.F., and Siegmund, B. (2022). Ileal and colonic Crohn's disease: Does location makes a difference in therapy efficacy? Curr Res Pharmacol Drug Discov *3*, 100097. 10.1016/j.crphar.2022.100097.

35.   Richard, N., Savoye, G., Leboutte, M., Amamou, A., Ghosh, S., and Marion-Letellier, R. (2023). Crohn's disease: Why the ileum? World J Gastroenterol *29*, 3222-3240. 10.3748/wjg.v29.i21.3222.

36.   Rieder, F., Zimmermann, E.M., Remzi, F.H., and Sandborn, W.J. (2013). Crohn's disease complicated by strictures: a systematic review. Gut *62*, 1072-1084. 10.1136/gutjnl-2012-304353.

37.   Sahoo, D., Swanson, L., Sayed, I.M., Katkar, G.D., Ibeawuchi, S.R., Mittal, Y., Pranadinata, R.F., Tindle, C., Fuller, M., Stec, D.L., et al. (2021). Artificial intelligence guided discovery of a barrier-protective therapy in inflammatory bowel disease. Nat Commun *12*, 4246. 10.1038/s41467-021-24470-5.

38.   Katkar, G.D., Sayed, I.M., Anandachar, M.S., Castillo, V., Vidales, E., Toobian, D., Usmani, F., Sawires, J.R., Leriche, G., Yang, J., et al. (2022). Artificial intelligence-rationalized balanced PPARalpha/gamma dual agonism resets dysregulated macrophage processes in inflammatory bowel disease. Commun Biol *5*, 231. 10.1038/s42003-022-03168-4.

39.   Arnott, I.D., McNeill, G., and Satsangi, J. (2003). An analysis of factors influencing short-term and sustained response to infliximab treatment for Crohn's disease. Aliment Pharmacol Ther *17*, 1451-1457. 10.1046/j.1365-2036.2003.01574.x.

40.   Dulai, P.S., Boland, B.S., Singh, S., Chaudrey, K., Koliani-Pace, J.L., Kochhar, G., Parikh, M.P., Shmidt, E., Hartke, J., Chilukuri, P., et al. (2018). Development and Validation of a Scoring System to Predict Outcomes of Vedolizumab Treatment in Patients With Crohn's Disease. Gastroenterology *155*, 687-695 e610. 10.1053/j.gastro.2018.05.039.

41.   Xu, M., Tchkonia, T., Ding, H., Ogrodnik, M., Lubbers, E.R., Pirtskhalava, T., White, T.A., Johnson, K.O., Stout, M.B., Mezera, V., et al. (2015). JAK inhibition alleviates the cellular senescence-associated secretory phenotype and frailty in old age. Proc Natl Acad Sci U S A *112*, E6301-6310. 10.1073/pnas.1515386112.

42.   Kinchen, J., Chen, H.H., Parikh, K., Antanaviciute, A., Jagielowicz, M., Fawkner-Corbett, D., Ashley, N., Cubitt, L., Mellado-Gomez, E., Attar, M., et al. (2018). Structural Remodeling of the Human Colonic Mesenchyme in Inflammatory Bowel Disease. Cell *175*, 372-386 e317. 10.1016/j.cell.2018.08.067.

43.   Williet, N., Sandborn, W.J., and Peyrin-Biroulet, L. (2014). Patient-reported outcomes as primary end points in clinical trials of inflammatory bowel disease. Clin Gastroenterol Hepatol *12*, 1246-1256 e1246. 10.1016/j.cgh.2014.02.016.

A Living Organoid Biobank of Crohn's Disease Patients Reveals Distinct Clinical Correlates of Molecular Subtypes of Disease

Authors:

Harrison M. Penrose[2,3], Saptarshi Sinha[1], Courtney Tindle[1,2], Kameron Zablan[3], Helen N. Le[3], Jennifer Neil[3], Pradipta Ghosh[1,2,3†¶], and Brigid S. Boland[3†¶]

Affiliations:

[1]*Department of Cellular and Molecular Medicine, University of California San Diego, La Jolla, CA, 92093.*

[2]*HUMANOID™ Center of Research Excellence (CoRE), University of California San Diego, La Jolla, CA, 92093.*

[3]*Department of Medicine, University of California San Diego, La Jolla, CA, 92093.*

Keywords: Patient-derived organoids, inflammatory bowel disease, personalized therapeutics, predictive disease models

†Senior corresponding authors:

Pradipta Ghosh, M.D.; prghosh@ucsd.edu

Brigid S. Boland, M.D; bboland@health.ucsd.edu

¶Lead contacts:

Pradipta Ghosh, M.D.; prghosh@ucsd.edu

Brigid S. Boland, M.D; bboland@health.ucsd.edu

INVENTORY OF SUPPLEMENTARY ONLINE MATERIALS

- Supplementary Figure and Legend (1)
- Supplemental Tables (Uploaded separately as Excel spreadsheets; Table S1-S2)

Supplementary Figure S1

Significant covariates are not independent and exhibit interdependence, potentially indicating
multicollinearity.

Multivariate analysis of *IDICD* vs. *S2FCD* subtypes as a linear combination of previously identified significant
(p<0.1) covariates (**Fig 1C**) from the same CD cohort. The coefficient of each variable (at the center) with
95% CI (as error bars) and the p values are illustrated. The p-value for each term tests the null hypothesis
0 that the coefficient is equal to zero (no effect). p≤ 0.1; *p ≤ 0.05; **p ≤ 0. 01. IC, ileocecal; NSNP, non-
1 stricturing, non-penetrating; ∆ refers the delta change between follow-up and baseline PRO scores.